■非靶向代谢组学为肌少症的发病机制提供了新的见解。在这项研究中,我们在一项基于LC-MS的非靶向代谢组学的队列研究中探讨了与肌肉减少症风险增加相关的血浆代谢特征.
■在这项来自成人体质与健康队列研究(APFHCS)的嵌套病例对照研究中,我们收集了30例新发肌少症患者(平均年龄73.2±5.6岁)和30例健康对照(平均年龄74.2±4.6岁)的血浆样本,性别,BMI,生活方式,和合并症。采用非靶向代谢组学方法来辨别新诊断的肌肉减少症个体中存在的代谢组学改变。
■将新发肌少症患者与正常对照组进行比较,使用液相色谱-质谱(LC-MS)进行的综合分析确定了总共62种代谢物,主要包含脂质,类脂分子,有机酸,和衍生品。受试者工作特征(ROC)曲线分析表明,3种代谢产物次黄嘌呤(AUC=0.819,95%CI=0.711-0.927),L-2-氨基-3-氧代丁酸(AUC=0.733,95%CI=0.598-0.868)和PC(14:0/20:2(11Z,14Z))(AUC=0.717,95%CI=0.587-0.846)的曲线下面积最高。然后,这些显著的代谢物被观察到显著富集在四个不同的代谢途径,即,“嘌呤代谢”;“甲状旁腺激素合成,分泌和作用“;”癌症中的胆碱代谢“;”和“结核病”。
■当前的研究阐明了在诊断为肌少症的个体中观察到的代谢扰动。鉴定的代谢物有望成为潜在的生物标志物,为探索与肌少症相关的潜在病理机制提供了途径。
UNASSIGNED: Untargeted metabonomics has provided new insight into the pathogenesis of sarcopenia. In this study, we explored plasma metabolic signatures linked to a heightened risk of sarcopenia in a cohort study by LC-MS-based untargeted metabonomics.
UNASSIGNED: In this nested case-control study from the Adult Physical Fitness and Health Cohort Study (APFHCS), we collected blood plasma samples from 30 new-onset sarcopenia subjects (mean age 73.2 ± 5.6 years) and 30 healthy controls (mean age 74.2 ± 4.6 years) matched by age, sex, BMI, lifestyle, and comorbidities. An untargeted metabolomics methodology was employed to discern the metabolomic profile alterations present in individuals exhibiting newly diagnosed sarcopenia.
UNASSIGNED: In comparing individuals with new-onset sarcopenia to normal controls, a comprehensive analysis using liquid chromatography-mass spectrometry (LC-MS) identified a total of 62 metabolites, predominantly comprising lipids, lipid-like molecules, organic acids, and derivatives. Receiver operating characteristic (ROC) curve analysis indicated that the three metabolites
hypoxanthine (AUC=0.819, 95% CI=0.711-0.927), L-2-amino-3-oxobutanoic acid (AUC=0.733, 95% CI=0.598-0.868) and PC(14:0/20:2(11Z,14Z)) (AUC= 0.717, 95% CI=0.587-0.846) had the highest areas under the curve. Then, these significant metabolites were observed to be notably enriched in four distinct metabolic pathways, namely, \"purine metabolism\"; \"parathyroid hormone synthesis, secretion and action\"; \"choline metabolism in cancer\"; and \"tuberculosis\".
UNASSIGNED: The current investigation elucidates the metabolic perturbations observed in individuals diagnosed with sarcopenia. The identified metabolites hold promise as potential biomarkers, offering avenues for exploring the underlying pathological mechanisms associated with sarcopenia.